



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 209/40, A61K 31/395, A61P 43/00, C07D 413/06, 405/06, 417/06, 401/06, 403/06, 409/04, 409/14, 405/14, 417/14, 401/14, C07F 7/10		A1	(11) International Publication Number: WO 00/64872 (43) International Publication Date: 2 November 2000 (02.11.00)
(21) International Application Number: PCT/US00/10866 (22) International Filing Date: 21 April 2000 (21.04.00)		(74) Agents: HALEY, James, F., Jr.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US) et al.	
(30) Priority Data: 60/130,752 23 April 1999 (23.04.99) US		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 130 Waverly Street, Cambridge, MA 02139-4242 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SALITURO, Francesco, Gerald [US/US]; 25 Baker Drive, Marlborough, MA 01752 (US). BEMIS, Guy, W. [US/US]; 256 Appleton Street, Arlington, MA 02476 (US). WILKE, Susanne [DE/US]; 16 Rindgefield Street, Cambridge, MA 02140 (US). GREEN, Jeremy [US/US]; 21 Greystone, Burlington, MA 01803 (US). CAO, Jingrong [CN/US]; 45 Madison Avenue, Newton, MA 02460 (US). GAO, Huai [CN/US]; 26 Lane's End, Natick, MA 01760 (US). HARRINGTON, Edmund, Martin [IE/US]; Apartment #21, 284 Harvard Street, Cambridge, MA 02139 (US).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)			
(57) Abstract			
<p>The present invention relates to compounds of formula (I) or (II), or a pharmaceutically acceptable derivative or prodrug thereof; wherein Y is selected from $-(CH_2)-Q_1$; $-(CO)-Q_1$; $-(CO)NH-Q_1$; $-(CO)O-Q_1$ or $-(SO_2)O-Q_1$; $-(SO_2)NH-Q_1$; Q_1 is a C₁-C₆ straight chain or branched alkyl or alkenyl group; a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring; or a 9-14 membered bicyclic or tricyclic aromatic or non-aromatic carbocyclic or heterocyclic ring system, W is N or C; Z is CH or N, which are inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.</p>			
<hr/> ATTORNEY DOCKET NUMBER: 10624-053-999 SERIAL NUMBER: 10/071,390 REFERENCE: AH			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	Sf	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)TECHNICAL FIELD OF INVENTION

The present invention relates to inhibitors of c-Jun N-terminal kinases (JNK), which are members of the mitogen-activated protein (MAP) kinase family. There are a number of different genes and isoforms which encode JNKs. Members of the JNK family regulate signal transduction in response to environmental stress and proinflammatory cytokines and have been implicated to have a role in mediating a number of different disorders. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.

BACKGROUND OF THE INVENTION

Mammalian cells respond to extracellular stimuli by activating signaling cascades that are mediated by members of the mitogen-activated protein (MAP) kinase family, which include the extracellular signal regulated kinases (ERKs), the p38 MAP kinases and the c-Jun N-terminal kinases (JNKs). MAP kinases (MAPKs) are activated by a variety of signals including growth factors, cytokines, UV radiation, and stress-inducing agents. MAPKs are serine/threonine kinases and their activation occur by dual phosphorylation of threonine and tyrosine at the Thr-X-Tyr segment in the activation loop.

-2-

MAPKs phosphorylate various substrates including transcription factors, which in turn regulate the expression of specific sets of genes and thus mediate a specific response to the stimulus.

5 One particularly interesting kinase family are the c-Jun NH₂-terminal protein kinases, also known as JNKs. Three distinct genes, JNK1, JNK2, JNK3 have been identified and at least ten different splicing isoforms of JNKs exist in mammalian cells [Gupta et al., EMBO J.,
10 15:2760-70 (1996)]. Members of the JNK family are activated by proinflammatory cytokines, such as tumor necrosis factor- α (TNF α) and interleukin-1 β (IL-1 β), as well as by environmental stress, including anisomycin, UV irradiation, hypoxia, and osmotic shock [Minden et al.,
15 Biochemica et Biophysica Acta, 1333:F85-F104 (1997)].

The down-stream substrates of JNKs include transcription factors c-Jun, ATF-2, Elk1, p53 and a cell death domain protein (DENN) [Zhang et al. Proc. Natl. Acad. Sci. USA, 95:2586-91 (1998)]. Each JNK isoform binds to these substrates with different affinities, suggesting a regulation of signaling pathways by substrate specificity of different JNKs *in vivo* (Gupta et al., *supra*).

JNKs, along with other MAPKs, have been implicated in having a role in mediating cellular response to cancer, thrombin-induced platelet aggregation, immunodeficiency disorders, autoimmune diseases, cell death, allergies, osteoporosis and heart disease. The therapeutic targets related to activation of the JNK pathway include chronic myelogenous leukemia (CML), rheumatoid arthritis, asthma, osteoarthritis, ischemia, cancer and neurodegenerative diseases.

-3-

Several reports have detailed the importance of JNK activation associated with liver disease or episodes of hepatic ischemia [Nat. Genet. 21:326-9 (1999); FEBS Lett. 420:201-4 (1997); J. Clin. Invest. 102:1942-50 (1998); Hepatology 28:1022-30 (1998)]. Therefore, 5 inhibitors of JNK may be useful to treat various hepatic disorders.

A role for JNK in cardiovascular disease such as myocardial infarction or congestive heart failure has also 10 been reported as it has been shown JNK mediates hypertrophic responses to various forms of cardiac stress [Circ. Res. 83:167-78 (1998); Circulation 97:1731-7 (1998); J. Biol. Chem. 272:28050-6 (1997); Circ. Res. 79:162-73 (1996); Circ. Res. 78:947-53 (1996); J. Clin. 15 Invest. 97:508-14 (1996)].

It has been demonstrated that the JNK cascade also plays a role in T-cell activation, including activation of the IL-2 promoter. Thus, inhibitors of JNK may have therapeutic value in altering pathologic immune 20 responses [J. Immunol. 162:3176-87 (1999); Eur. J. Immunol. 28:3867-77 (1998); J. Exp. Med. 186:941-53 (1997); Eur. J. Immunol. 26:989-94 (1996)].

A role for JNK activation in various cancers has also been established, suggesting the potential use of JNK 25 inhibitors in cancer. For example, constitutively activated JNK is associated with HTLV-1 mediated tumorigenesis [Oncogene 13:135-42 (1996)]. JNK may play a role in Kaposi's sarcoma (KS) because it is thought that the proliferative effects of bFGF and OSM on KS cells are 30 mediated by their activation of the JNK signaling pathway [J. Clin. Invest. 99:1798-804 (1997)]. Other proliferative effects of other cytokines implicated in KS

-4-

proliferation, such as vascular endothelial growth factor (VEGF), IL-6 and TNF α , may also be mediated by JNK. In addition, regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK,
5 suggesting a role for JNK inhibitors in the treatment for chronic myelogenous leukemia (CML) [Blood 92:2450-60 (1998)].

JNK1 and JNK2 are widely expressed in a variety of tissues. In contrast, JNK3, is selectively expressed in
10 the brain and to a lesser extent in the heart and testis [Gupta et al., *supra*; Mohit et al., Neuron 14:67-78 (1995); Martin et al., Brain Res. Mol. Brain Res. 35:47-57 (1996)]. JNK3 has been linked to neuronal apoptosis induced by kainic acid, indicating a role of JNK in the
15 pathogenesis of glutamate neurotoxicity. In the adult human brain, JNK3 expression is localized to a subpopulation of pyramidal neurons in the CA1, CA4 and subiculum regions of the hippocampus and layers 3 and 5 of the neocortex [Mohit et al., *supra*]. The CA1 neurons of
20 patients with acute hypoxia showed strong nuclear JNK3-immunoreactivity compared to minimal, diffuse cytoplasmic staining of the hippocampal neurons from brain tissues of normal patients [Zhang et al., *supra*]. Thus, JNK3 appears to be involved in hypoxic and ischemic damage of
25 CA1 neurons in the hippocampus.

In addition, JNK3 co-localizes immunochemically with neurons vulnerable in Alzheimer's disease [Mohit et al., *supra*]. Disruption of the JNK3 gene caused resistance of mice to the excitotoxic glutamate receptor
30 agonist kainic acid, including the effects on seizure activity, AP-1 transcriptional activity and apoptosis of hippocampal neurons, indicating that the JNK3 signaling

-5-

pathway is a critical component in the pathogenesis of glutamate neurotoxicity (Yang et al., Nature, 389:865-870 (1997)).

Based on these findings, JNK signalling, especially that of JNK3, has been implicated in the areas of apoptosis-driven neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, ALS (Amyotrophic Lateral Sclerosis), epilepsy and seizures, Huntington's Disease, traumatic brain injuries, as well as ischemic and hemorrhaging stroke.

There is a high unmet medical need to develop JNK specific inhibitors that are useful in treating the various conditions associated with JNK activation, especially considering the currently available, relatively inadequate treatment options for the majority of these conditions.

Recently, we have described crystallizable complexes of JNK protein and adenosine monophosphate, including complexes comprising JNK3, in U.S. Provisional Application 60/084056, filed May 4, 1998. Such information has been extremely useful in identifying and designing potential inhibitors of various members of the JNK family, which, in turn, have the described above therapeutic utility.

Much work has been done to identify and develop drugs that inhibit MAPKs, such as p38 inhibitors. See, e.g., WO 98/27098 and WO 95/31451. However, to our knowledge, no MAPK inhibitors have been shown to be specifically selective for JNKs versus other related MAPKs.

Accordingly, there is still a great need to develop potent inhibitors of JNKs, including JNK3


-6-

inhibitors, that are useful in treating various conditions associated with JNK activation.

SUMMARY OF THE INVENTION

5 The present invention addresses this problem by
providing compounds that demonstrate strong inhibition of
JNK.

These compounds have the general formulae:



10 or pharmaceutically acceptable derivatives or prodrugs
thereof.

γ is selected from $-(CH_2)-Q_1$; $-(CO)-Q_1$; $-(CO)NH-Q_1$; $-(CO)O-Q_1$; $-(SO_2)-Q_1$ or $-(SO_2)NH-Q_1$.

Q₁ is a C₁-C₆ straight chain or branched alkyl or alkenyl group; a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring; or a 9-14 membered bicyclic or tricyclic aromatic or non-aromatic carbocyclic or heterocyclic ring system, wherein said alkyl, alkenyl, ring or ring system is optionally substituted with one to four substituents, each of which is independently selected from NH₂, NH-R, N(R)₂, NO₂, OH, OR, CF₃, halo, CN, CO₂H, C(O)-NH₂, C(O)-NH-R, C(O)-N(R)₂, C(O)-R, SR, S(O)-R, S(O)₂R, R-S(=O)R, R-S(=O)₂R, NW, E, or R.

25 A heterocyclic ring system or a heterocyclic ring as defined herein is one that contains 1 to 4

-7-

heteroatoms, which are independently selected from N, O, S, SO and SO₂.

W is N or C. When W is N, R₈ is a lone pair of electrons. When W is C, R₈ is R₇.

5 A₁ is N or CR¹;

A₂ is N or CR²;

A₃ is N or CR³;

A₄ is N or CR⁴;

provided that at least one of A₁, A₂, A₃ and A₄

10 must not be N.

R¹ is -NHR⁵, -OR⁵, -SR⁵, or -R⁵.

R², R³, and R⁴ are independently selected from -(CO)NH₂, -(CO)NHR, -(CO)N(R)₂, -NHR⁵, -NHCH₂R⁵, -OR⁵, -SR⁵, -R⁵, -NH(CO)-R⁶, -NH(CO)-NHR⁶, -NH(CO)-NH(CO)R⁶, -NH(CO)-OR⁶, 15 -NH(SO₂)-R⁶, -NH(SO₂)-NHR⁶, -C(O)OH, -C(O)OR, -(CO)-Q₁, -(CO)NH-Q₁, -(CO)NR-Q₁, -(CO)-O-Q₁, -(SO₂)-Q₁ or -(SO₂)NH-Q₁.

R⁵ and R⁶ are each independently selected from H; N(R)₂, NHOH, NO₂, C(O)OR or halo; a C₁-C₆ straight chain or branched alkyl, alkenyl or alkynyl group; a 5-7 membered 20 aromatic or non-aromatic carbocyclic or heterocyclic ring; or a 9-14 membered bicyclic or tricyclic aromatic or non-aromatic carbocyclic or heterocyclic ring, wherein said alkyl, alkenyl, ring or ring system is optionally substituted with one to four substituents, each of which 25 is independently selected from NH₂, NHR, NHC(O)OR, N(R)₂, NO₂, OH, OR, CF₃, halo, CN, Si(R)₃, CO₂H, COOR, CONH₂, CONHR, CON(R)₂, COR, SR, S(O)R, S(O)₂R, S(O)₂NHR or R.

R⁷ is H; a C₁-C₆ straight chain or branched alkyl 30 or alkenyl group; a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring; or a 9-14 membered bicyclic or tricyclic aromatic or non-aromatic carbocyclic or heterocyclic ring; wherein said alkyl, alkenyl, ring or

-8-

ring system is optionally substituted with one to four substituents, each of which is independently selected from NH₂, NHR, N(R)₂, NO₂, OH, OR, CF₃, halo, CN, CO₂H, CONH₂, CONHR, CON(R)₂, COR, SR, S(O)R, S(O)₂R, S(O)₂NHR or R.

5 R is a C₁-C₆ straight chain or branched alkyl or alkenyl group, a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring, or a 9-10 membered bicyclic aromatic or non-aromatic carbocyclic or heterocyclic ring system.


10 Z is CH or N.

In another embodiment, the invention provides pharmaceutical compositions comprising the JNK inhibitors of this invention. These compositions may be utilized in methods for treating or preventing a variety of disorders, such as heart disease, immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, destructive bone disorders such as osteoporosis, proliferative disorders, infectious diseases and viral diseases. These compositions are also useful in methods for preventing cell death and hyperplasia and therefore may be used to treat or prevent reperfusion/ischemia in stroke, heart attacks, and organ hypoxia. The compositions are also useful in methods for preventing thrombin-induced platelet aggregation. The compositions are especially useful for disorders such as chronic myelogenous leukemia (CML), rheumatoid arthritis, asthma, osteoarthritis, ischemia, cancer, liver disease including hepatic ischemia, heart disease such as myocardial infarction and congestive heart failure, pathologic immune conditions involving T cell activation and neurodegenerative disorders. Each of these above-described methods is also part of the present invention.

-9-

DETAILED DESCRIPTION OF THE INVENTION

These compounds have the general formulae:



or pharmaceutically acceptable derivatives or prodrugs
5 thereof.

Y is selected from -(CH₂)_n-Q₁; -(CO)-Q₁; -(CO)NH-Q₁; -(CO)O-Q₁; -(SO₂)-Q₁ or -(SO₂)NH-Q₁.

Q₁ is a C₁-C₆ straight chain or branched alkyl or alkenyl group; a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring; or a 9-14 membered bicyclic or tricyclic aromatic or non-aromatic carbocyclic or heterocyclic ring system, wherein said alkyl, alkenyl, ring or ring system is optionally substituted with one to four substituents, each of which is independently selected
10 from NH₂, NH-R, N(R)₂, NO₂, OH, OR, CF₃, halo, CN, CO₂H,
carbocyclic or heterocyclic ring; or a 9-14 membered
15 bicyclic or tricyclic aromatic or non-aromatic carbocyclic or heterocyclic ring system, wherein said alkyl, alkenyl, ring or ring system is optionally substituted with one to four substituents, each of which is independently selected
from NH₂, NH-R, N(R)₂, NO₂, OH, OR, CF₃, halo, CN, CO₂H,
C(O)-NH₂, C(O)-NH-R, C(O)-N(R)₂, C(O)-R, SR, S(O)-R,
S(O)₂-R, S(O)₂-NH-R or -R.

A heterocyclic ring system or a heterocyclic ring as defined herein is one that contains 1 to 4 heteroatoms, which are independently selected from N, O, S, SO and SO₂.

W is N or C. When W is N, R₈ is a lone pair of electrons. When W is C, R₈ is R₇.

25 A₁ is N or CR¹;
A₂ is N or CR²;

-10-

A₃ is N or CR³;

A₄ is N or CR⁴;

provided that at least one of A₁, A₂, A₃ and A₄

must not be N.

5 R¹ is -NHR⁵, -OR⁵, -SR⁵, or -R⁵.

R², R³, and R⁴ are independently selected from -
(CO)NH₂, -(CO)NHR, -(CO)N(R)₂, -NHR⁵, -NHCH₂R⁵, -OR⁵, -SR⁵, -
R⁵, -NH(CO)-R⁶, -NH(CO)-NHR⁶, -NH(CO)-NH(CO)R⁶, -NH(CO)-OR⁶,
-NH(SO₂)-R⁶, -NH(SO₂)-NHR⁶, -C(O)OH, -C(O)OR, -(CO)-Q₁, -
10 (CO)NH-Q₁, -(CO)NR-Q₁, -(CO)-O-Q₁, -(SO₂)-Q₁ or -(SO₂)NH-Q₁.

R⁵ and R⁶ are each independently selected from H;
N(R)₂, NHOH, NO₂, C(O)OR or halo; a C₁-C₆ straight chain or
branched alkyl, alkenyl or alkynyl group; a 5-7 membered
aromatic or non-aromatic carbocyclic or heterocyclic ring;
15 or a 9-14 membered bicyclic or tricyclic aromatic or non-
aromatic carbocyclic or heterocyclic ring optionally
substituted with one to four substituents, wherein said
alkyl, alkenyl, ring or ring system is optionally
substituted with one to four substituents, each of which
20 is independently selected from NH₂, NHR, NHC(O)OR, N(R)₂,
NO₂, OH, OR, CF₃, halo, CN, Si(R)₃, CO₂H, COOR, CONH₂,
CONHR, CON(R)₂, COR, SR, S(O)R, S(O)₂R, S(O)₂NHR or R.

R⁷ is H; a C₁-C₆ straight chain or branched alkyl
or alkenyl group, optionally substituted with one to four
25 substituents, each of which is independently selected from
NH₂, NHR, N(R)₂, NO₂, OH, OR, CF₃, halo, CN, CO₂H, CONH₂,
CONHR, CON(R)₂, COR, SR, S(O)R, S(O)₂R, S(O)₂NHR or R; a 5-
7 membered aromatic or non-aromatic carbocyclic or
heterocyclic ring, optionally substituted with one to four
30 substituents, each of which is independently selected from
NH₂, NHR, N(R)₂, NO₂, OH, OR, CF₃, halo, CN, CO₂H, CONH₂,
CONHR, CON(R)₂, COR, SR, S(O)R, S(O)₂R, S(O)₂NHR or R; or a


-11-

9-10 membered bicyclic aromatic or non-aromatic carbocyclic or heterocyclic ring optionally substituted with one to four substituents, each of which is independently selected from NH₂, NHR, N(R)₂, NO₂, OH, OR,
 5 CF₃, halo, CN, CO₂H, CONH₂, CONHR, CON(R)₂, COR, SR, S(O)R,
 S(O)₂R, S(O)₂NHR or R.

10 R is a C₁-C₆ straight chain or branched alkyl or alkenyl group, a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring, or a 9-10 membered bicyclic aromatic or non-aromatic carbocyclic or heterocyclic ring system.

Z is CH or N.

When Z is CH, the carbon is chiral. Both isomeric forms of the compound are encompassed by the instant invention. In addition, when Z is CH, the acidic nature of the CH proton can result in tautomeric structures of formula II, as shown below. These tautomeric structures,



20 are encompassed by the instant invention.

The present invention envisions all possible stereoisomers, enantiomers and racemic mixtures. For example, oxime compounds may exist in isomeric forms. The oxime compounds of this invention may exist as either an
 25 E-isomer, a Z-isomer, or a mixture of E- and Z-isomers.

According to a preferred embodiment, Y is

- (CH₂) -Q₁.

-12-

According to a preferred embodiment, Q₁ is benzodioxanyl, an optionally substituted phenyl group, a substituted heterocyclic ring, a 10-membered heterocyclic bicyclic ring, or a straight chain alkyl group substituted 5 with phenyl or a heterocyclic monocyclic or bicyclic ring.

According to a preferred embodiment, W is N and R⁸ is a lone pair of electrons.

According to a preferred embodiment, A₁ is CR¹.

According to a preferred embodiment, A₂ is CR² or 10 CR³.

According to a preferred embodiment, A₃ is CR² or CR³.

According to a preferred embodiment, A₄ is CR⁴.

According to a preferred embodiment, R¹ is R⁵.

15 In a more preferred embodiment, R¹ is H, methyl, halo, an optionally substituted phenyl, a monocyclic or bicyclic heterocycle, a substituted or unsubstituted alkyl, alkenyl or alkynyl, or COOR.

According to a preferred embodiment, R² is R⁵, 20 NH(CO)-R⁶, NH(SO₂)-R⁶, -NHCH₂R⁵, CO-Q₁ or CONH-Q₁. In a more preferred embodiment, R² is H, halo, NO₂, NH₂, methyl, OCF₃, -N(R)₂, or substituted phenyl.

According to a preferred embodiment, R³ is R⁵, 25 NH(CO)-R⁶, NH(SO₂)-R⁶, CONH-Q₁. In a more preferred embodiment, R³ is H, halo, methyl, CF₃, substituted or unsubstituted phenyl, a heterocyclic ring, a bicyclic ring, NO₂ or NH₂.

According to a preferred embodiment, R⁴ is R⁵.

In a more preferred embodiment, R⁴ is H or methyl.





30 Some specific examples of preferred compounds of the instant invention are provided in Tables 1 to 17 below. In Tables 1 to 17, "+" represents a K_i ≥ 1 μM,

-13-

"++" represents a $K_i < 1 \mu\text{M}$, and "ND" means not determined. The K_i is determined by the method disclosed in Example 3.

Table 1






5

Cmpd	Structure	K_i
1		+
2		++
3		+
4		++






-14-

5		++
6		+
7		++
8		+
9		+






-15-

10		+
11		+
12		+
13		++
14		+





-16-

15		+
16		ND
17		+
18		+
19		+





-17-

20		+
21		+
22		ND
23		+
24		+





-18-

25		+
26		+
27		+
28		+





-19-

29		+
30		ND
31		ND
32		ND





-20-

33		+
34		+
35		ND
36		ND





-21-

37	 Chemical structure 37 is a substituted imidazolidine derivative. It features a central imidazolidine ring with a hydroxyl group at position 3 and a carbonyl group at position 4. A phenylmethyl group is attached to the nitrogen atom at position 2. A methyl group is attached to the 5-position of the imidazolidine ring.	ND
38	 Chemical structure 38 is a substituted imidazolidine derivative. It features a central imidazolidine ring with a hydroxyl group at position 3 and a carbonyl group at position 4. A phenylmethyl group is attached to the nitrogen atom at position 2. A methyl group is attached to the 5-position of the imidazolidine ring. The 2-position of the phenyl ring has a fluorine atom attached.	ND
39	 Chemical structure 39 is a substituted imidazolidine derivative. It features a central imidazolidine ring with a hydroxyl group at position 3 and a carbonyl group at position 4. A phenylmethyl group is attached to the nitrogen atom at position 2. A methyl group is attached to the 5-position of the imidazolidine ring. The 2-position of the phenyl ring is substituted with a nitro group ($-O-N(O)O-$).	+
40	 Chemical structure 40 is a substituted imidazolidine derivative. It features a central imidazolidine ring with a hydroxyl group at position 3 and a carbonyl group at position 4. A phenylmethyl group is attached to the nitrogen atom at position 2. A methyl group is attached to the 5-position of the imidazolidine ring. The 2-position of the phenyl ring has a methyl group attached ($-CH_3$).	ND





-22-

41		ND
42		ND
43		ND
44		ND





-23-

45		+
46		+
47		+
48		+





-24-

49	 Chemical structure 49 is a substituted indolin-2-one. It features a 2-chlorophenyl group attached to the nitrogen atom at position 1. A 3-methylbutyl side chain is attached to the carbonyl carbon at position 2. The indolin-2-one ring is shown with its characteristic fused five-membered ring system.	+
50	 Chemical structure 50 is a substituted indolin-2-one. It features a 2-chlorophenyl group attached to the nitrogen atom at position 1. A phenyl group is attached to the carbonyl carbon at position 2. The indolin-2-one ring is shown with its characteristic fused five-membered ring system.	+
51	 Chemical structure 51 is a substituted indolin-2-one. It features a 2-chlorophenyl group attached to the nitrogen atom at position 1. A 4-fluorophenyl group is attached to the carbonyl carbon at position 2. The indolin-2-one ring is shown with its characteristic fused five-membered ring system.	+
52	 Chemical structure 52 is a substituted indolin-2-one. It features a 2-chlorophenyl group attached to the nitrogen atom at position 1. A 4-nitrophenyl group is attached to the carbonyl carbon at position 2. The indolin-2-one ring is shown with its characteristic fused five-membered ring system.	ND





-25-

53		ND
54		+
55		+
56		+





-26-

57		+
58		+
59		+
60		ND





-27-

61		+
62		++
63		+
64		+





-28-

65		+
66		+
67		+
68		++





-29-

69		++
70		+
71		+
72		+




-30-

73		+
74		++
75		++
76		+





-31-

77		++
78		+
79		+
80		+




-32-

81	 Chemical structure 81: A 2-(2-fluorophenyl)-3-hydroxy-4-methyl-5-phenyl-1,2-dihydroimidazol-2-one derivative. It consists of a 2-(2-fluorophenyl)imidazol-2-one core with a 4-methyl group and a 5-phenyl group attached to the imidazole ring.	+
82	 Chemical structure 82: A 2-(2-fluorophenyl)-3-hydroxy-4-phenyl-1,2-dihydroimidazol-2-one derivative. It consists of a 2-(2-fluorophenyl)imidazol-2-one core with a 4-phenyl group attached to the imidazole ring.	+
83	 Chemical structure 83: A 2-(2-fluorophenyl)-3-hydroxy-4-(4-methylsulfonylphenyl)-1,2-dihydroimidazol-2-one derivative. It consists of a 2-(2-fluorophenyl)imidazol-2-one core with a 4-(4-methylsulfonylphenyl) group attached to the imidazole ring.	+




-33-

84		++
85		++
86		+
87		+




-34-

88		+
89		+
90		+

-35-




91		+
92		+
93		+

-36-




94		+
95		+
96		+

-37-




97		+
98		++
99		+

100		+
101		+
102		++


-39-

103		++
104		+
105		+




-40-

106		+
107		+
108		+






-41-



-42-

112		ND
113		ND
114		ND






-43-

115		+
116		ND
117		ND
118		ND
119		ND

- 44 -

120		+
121		+
122		+
123		ND





-45-

124		ND
125		ND
126		ND
127		ND
128		ND





-46-

129		ND
130		ND
131		+
132		ND





-47-

133		ND
134		ND
135		ND
136		+





-48-

137		ND
138		ND
139		ND
140		ND





-49-

141		ND
142		ND
143		ND
144		ND





-50-

145		ND
146		ND
147		ND
148		ND





-51-

149		++
150		++
151		++
152		++

-52-

153		++
154		++
155		++
156		++

-53-

157		+
158		+
159		+
160		+

-54-

161		+
162		+
163		+
164		++

-55-

165		++
166		++
167		++
168		ND





-56-

169		ND
170		ND
171		ND




-57-

172		ND
173		ND
174		ND




-58-

175		+
176		+
177		ND
178		ND


-59-

179		ND
180		ND
181		ND




-60-

182		ND
183		+
184		+




- 61 -







- 62 -

188		+
189		++
190		+





- 63 -

191		ND
192		ND
193		ND




-64-

194		ND
195		ND
196		++
197		ND




-65-

198		+
199		++
200		+
201		++





-66-

202		+
203		+
204		+





-67-

205		+
206		+
207		++





- 68 -

208		++
209		++
210		++
211		ND





-69-

212		+
213		+
214		++
215		++





-70-

216		++
217		++
218		+
219		++





-71-

220		++
221		++
222		+
223		+





-72-

224		++
225		++
226		++
227		++

-73-

228		+
229		+
230		+
231		+





-74-

232		+
233		+
234		+
235		+




-75-

236		+
237		+
238		+
239		+





-76-

240		+
241		+
242		+
243		+





-77-

244		+
245		+
246		+





-78-

247		++
248		++
249		++
250		++





-79-

251		++
252		+
253		+
254		++





-80-




255		++
256		++
257		+
258		++

-81-





259		++
260		++
261		++
262		++

- 82 -





263		++
264		+
265		+
266		ND

267		ND
268		++
269		++




-84-

270		++
271		++
272		++
273		++





-85-

274		++
275		++
276		+
277		+





-86-

278		++
279		+
280		+





-87-

281		+
282		+
283		+
284		+





- 88 -

285		+
286		++
287		+
288		+





-89-

289		+
290		+
291		+
292		+





-90-

293		+
294		+
295		+
296		+




-91-

297		+
298		+
299		+
300		+


-92-

301		++
302		+
303		+
304		+




-93-

305		+
306		+
307		++

-94-







-95-

311		+
312		+
313		++





-96-

314		+
315		++
316		++
317		++





-97-

318		++
319		++
320		+
321		++





-98-

322		+
323		++
324		+
325		+





-99-

326		++
327		++
328		+
329		+





-100-

330		++
331		++
332		++
333		+

-101-

334		+
335		++
336		++
337		++





-102-

338		+
339		+
340		+
341		++





-103-

342		++
343		++
344		++
345		++




-104-

346		+
347		+
348		+
349		+

-105-

350		ND
351		+
352		+
353		ND

-106-

354		ND
355		++
356		++

According to another embodiment, the present invention provides methods of producing JNK inhibitors of the formulae I and II. Synthesis schemes for specific compounds are described in Examples 1 and 2.

Compounds of formula I, wherein W is N, may be prepared by standard synthetic methods, such as those described in Examples 1 and 2. Skilled practitioners would realize that these syntheses could be modified to provide other compound of formula I, wherein W is N.

-107-

Compounds of formula I, wherein W is C, may be prepared by standard synthetic methods, including the methods of Examples 1 and 2. Reaction of an appropriate oxindole in the presence of a compound of formula 5 R₈C(O)OCH₂CH₃ and a base, such as sodium ethoxide, in an appropriate solvent, such as ethanol would provide a substituted oxindole. Such a substituted oxindole could be subsequently reacted to form compounds of formula I, wherein W is C and R₈ is R₇ by, for example, the methods 10 described in Examples 1 and 2.

Compounds of formula II, wherein Z is C may be prepared by standard synthetic methods. For example, compounds of formula I, wherein Z is C may be prepared from an oxindole compound, such as compound B in Example 15 1. Reaction of an oxindole compound in the presence of ammonia, a reagent such as phosgene, an appropriate base, and an appropriate solvent would provide a compound that could be subsequently reacted to form compounds of formula I, wherein Z is C.

20 Compounds of formula II, wherein Z is N may be prepared as described in Example 3.

According to another embodiment of the invention, the activity of the JNK inhibitors of this invention may be assayed *in vitro*, *in vivo* or in a cell 25 line. *In vitro* assays include assays that determine inhibition of either the kinase activity or ATPase activity of activated JNK. For example, see Examples 3-5. Alternate *in vitro* assays quantitate the ability of the inhibitor to bind to JNK and may be measured either by 30 radiolabelling the inhibitor prior to binding, isolating the inhibitor/JNK complex and determining the amount of

-108-

radiolabel bound, or by running a competition experiment where new inhibitors are incubated with JNK bound to known radioligands. One may use any type or isoform of JNK, depending upon which JNK type or isoform is to be
5 inhibited.

The JNK inhibitors or pharmaceutical salts thereof may be formulated into pharmaceutical compositions for administration to animals or humans. These pharmaceutical compositions, which comprise an amount of
10 JNK inhibitor effective to treat or prevent a JNK-mediated condition and a pharmaceutically acceptable carrier, are another embodiment of the present invention.

The term "JNK-mediated condition", as used herein means any disease or other deleterious condition in
15 which JNK is known to play a role. Such conditions include, without limitation, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, cancer, infectious diseases, neurodegenerative diseases, allergies,
20 reperfusion/ischemia in stroke, heart attacks, angiogenic disorders, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin-induced platelet aggregation, and conditions associated with prostaglandin endoperoxidase synthase-2.

25 Inflammatory diseases which may be treated or prevented by the compounds of this invention include, but are not limited to, acute pancreatitis, chronic pancreatitis, asthma, allergies, and adult respiratory distress syndrome.

30 Autoimmune diseases which may be treated or prevented by the compounds of this invention include, but are not limited to, glomerulonephritis, rheumatoid

-109-

arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, 5 multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, or graft vs. host disease.

Destructive bone disorders which may be treated 10 or prevented by the compounds of this invention include, but are not limited to, osteoporosis, osteoarthritis and multiple myeloma-related bone disorder.

Proliferative diseases which may be treated or prevented by the compounds of this invention include, but 15 are not limited to, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma and HTLV-1 mediated tumorigenesis.

Angiogenic disorders which may be treated or 20 prevented by the compounds of this invention include solid tumors, ocular neovascularization, infantile haemangiomas. Infectious diseases which may be treated or prevented by the compounds of this invention include, but are not limited to, sepsis, septic shock, and Shigellosis.

Viral diseases which may be treated or prevented 25 by the compounds of this invention include, but are not limited to, acute hepatitis infection (including hepatitis A, hepatitis B and hepatitis C), HIV infection and CMV retinitis.

Neurodegenerative diseases which may be treated 30 or prevented by the compounds of this invention include, but are not limited to, Alzheimer's disease, Parkinson's

-110-

disease, amyotrophic lateral sclerosis (ALS), epilepsy, seizures, Huntington's disease, traumatic brain injury, ischemic and hemorrhaging stroke, cerebral ischemias or neurodegenerative disease, including apoptosis-driven 5 neurodegenerative disease, caused by traumatic injury, acute hypoxia, ischemia or glutamate neurotoxicity.

"JNK-mediated conditions" also include ischemia/reperfusion in stroke, heart attacks, myocardial ischemia, organ hypoxia, vascular hyperplasia, cardiac 10 hypertrophy, hepatic ischemia, liver disease, congestive heart failure, pathologic immune responses such as that caused by T cell activation and thrombin-induced platelet aggregation.

In addition, JNK inhibitors of the instant 15 invention may be capable of inhibiting the expression of inducible pro-inflammatory proteins. Therefore, other "JNK-mediated conditions" which may be treated by the compounds of this invention include edema, analgesia, fever and pain, such as neuromuscular pain, headache, 20 cancer pain, dental pain and arthritis pain.

In addition to the compounds of this invention, pharmaceutically acceptable derivatives or prodrugs of the compounds of this invention may also be employed in compositions to treat or prevent the above-identified 25 disorders.

A "pharmaceutically acceptable derivative or prodrug" means any pharmaceutically acceptable salt, ester, salt of an ester or other derivative of a compound of this invention which, upon administration to a 30 recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.

-111-

Particularly favored derivatives or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be 5 more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.

Pharmaceutically acceptable prodrugs of the 10 compounds of this invention include, without limitation, esters, amino acid esters, phosphate esters, metal salts and sulfonate esters.

Pharmaceutically acceptable salts of the 15 compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, 20 digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2- 25 naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, tosylate and undecanoate. Other acids, such as oxalic, while not in 30 themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their

-112-

pharmaceutically acceptable acid addition salts.

Salts derived from appropriate bases include alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and N-(C1-4 alkyl)4+ salts. This

5 invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.

Pharmaceutically acceptable carriers that may be
10 used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures
15 of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances,
20 polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

The compositions of the present invention may be administered orally, parenterally, by inhalation spray,
25 topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial
30 injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously.

-113-

Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or 5 wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and 10 solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its 15 glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or 20 suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used 25 surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.

30 The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to,

-114-

capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation.

Topically-transdermal patches may also be used.

For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in

-115-

one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene,
5 polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers
10 include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in
20 an ointment such as petrolatum.

The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
25

30 The amount of JNK inhibitor that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated, the particular

-116-

mode of administration. Preferably, the compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.

5 It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, 10 rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of inhibitor will also depend upon the particular compound in the composition.

According to another embodiment, the invention 15 provides methods for treating or preventing a JNK-mediated condition comprising the step of administering to a patient one of the above-described pharmaceutical compositions. The term "patient", as used herein, means an animal, preferably a human.

20 Preferably, that method is used to treat or prevent a condition selected from inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, neurodegenerative diseases, allergies, 25 reperfusion/ischemia in stroke, heart attacks, angiogenic disorders, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, and thrombin-induced platelet aggregation, or any specific disease or disorder described above.

Depending upon the particular JNK-mediated 30 condition to be treated or prevented, additional drugs, which are normally administered to treat or prevent that condition, may be administered together with the


-117-

inhibitors of this invention. For example, chemotherapeutic agents or other anti-proliferative agents may be combined with the JNK inhibitors of this invention to treat proliferative diseases.

5 Those additional agents may be administered separately, as part of a multiple dosage regimen, from the JNK inhibitor-containing composition. Alternatively, those agents may be part of a single dosage form, mixed together with the JNK inhibitor in a single composition.

10 In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.

-118-

EXAMPLE 1Synthesis of JNK Inhibitor Compound 152

One equivalent of 2-nitro-4-bromobenzenes bromide,

1.1 equivalents of diethyl malonate and 2.2 equivalents of sodium hydroxide was suspended in dimethyl sulfoxide

- 5 (DMSO) and stirred at $80^\circ C$ for 24 hours (h). Thin layer chromatography (TLC) was used to indicate that the reaction was complete. The reaction mixture was then cooled to room temperature, acidified with 2N HCl, then extracted with

-119-

ethyl acetate. The organic phase was washed with saturated NaCl 3 times and dried with MgSO₄. The solvent was removed under reduced pressure. Compound A was purified by chromatography. The yield was 78%.

5 One equivalent of compound A and 3 equivalents of Fe were refluxed in acetic acid for 3 h, then the reaction mixture was cooled to room temperature. Saturated NaCl and ethyl acetate was added to the reaction mixture, the organic phase was washed with saturated NaCl
10 3 times, dried with MgSO₄, and the solvent was removed under reduced pressure. Compound B was purified by chromatography. The yield was 90%.

To one equivalent of compound B, 1.4 equivalents of sodium ethoxide in ethyl alcohol was added at room
15 temperature. The reaction mixture was stirred at 60°C for 1 h, then 3.7 equivalents of ethylformate was added to the mixture. The mixture was stirred at 60°C for 30 minutes, during which time a large amount of precipitate was formed. TLC indicated that the reaction was complete.
20 The reaction mixture was cooled to room temperature. 1N HCl was added to the reaction mixture. The reaction mixture was then filtered to yield a filtration cake, which was compound C. The yield was great than 95%.

To one equivalent of compound C, 1.2 equivalents of a K₂CO₃/DMF suspension was added. 1.2 equivalents of methoxy-O-methyl chloride (MOMCl) was added at room temperature slowly until TLC indicated that there was no more compound C present. Saturated NaCl and ethyl acetate was added to the reaction mixture. The organic phase was
30 washed with saturated NaCl 3 times and then was dried with MgSO₄. The solvent was removed under reduced pressure. Compound D was purified by chromatography. The yield was

-120-

80%.

One equivalent of Compound D was dissolved in a 4 to 1 ratio of tert-butanol (*t*-BuOH)/dioxane solution. Three equivalents of a saturated aqueous K₂CO₃ solution was 5 added to the reaction mixture, followed by 16 equivalents of a NaIO₄ saturated solution and 0.25 equivalents of a KMnO₄ saturated solution. The reaction mixture was stirred at room temperature for 1 h. TLC indicated the reaction was completed. Ethyl acetate and H₂O was added to the 10 reaction mixture, the organic phase was washed with saturated NaCl 3 times, dried with MgSO₄ and the solvent was removed under reduced pressure. The residue was compound E. The yield was 88%.


One equivalent of Compound E was mixed with 1.2 15 equivalents of 8-(chloromethyl)-6-fluorobenzo-1,3-dioxan and 1.2 equivalents of K₂CO₃ in a DMF suspension and stirred at room temperature overnight. TLC indicated the reaction was complete. Saturated NaCl and ethyl acetate was added to the reaction mixture, the organic phase was 20 washed with saturated NaCl 3 times, dried with MgSO₄, and the solvent was removed under reduced pressure. Compound F was purified by chromatography. The yield was 80%.

One equivalent of Compound F, 1.3 equivalents of hydroxylamine hydrochloride and 2.6 equivalents of K₂CO₃ 25 in a DMF suspension were stirred together at room temperature overnight. TLC indicated the reaction was complete. Saturated NaCl and ethyl acetate was added to the reaction mixture, the organic phase was washed with saturated NaCl 3 times, dried with MgSO₄, and the solvent 30 was removed under reduced pressure. Compound 152 was purified by chromatography.

-121-

EXAMPLE 2

Synthesis of JNK Inhibitor Compound 153



One equivalent of Compound F (prepared as in
5 Example 1), 1.2 eq of phenyl boronic acid, Na₂CO₃, and a catalytical amount of tetrakis triphenylphosphine palladium toluene was suspended in water and stirred at 80°C overnight. Saturated NaCl and ethyl acetate was added to the reaction mixture, the organic phase was dried with 10 MgSO₄, and the solvent was removed under reduced pressure. Compound G was purified by chromatography. The yield was 64%.


One equivalent of Compound G, 1.3 equivalents of hydroxylamine hydrochloride and 2.6 equivalents of K_2CO_3 in a DMF suspension were stirred together at room temperature overnight. TLC indicated the reaction was complete. Saturated NaCl and ethyl acetate was added to the reaction mixture, the organic phase was washed with saturated NaCl 3 times, dried with $MgSO_4$, and the solvent was removed under reduced pressure. Compound 153 was

-122-

purified by chromatography.

EXAMPLE 3

5 Solid Phase Synthesis of JNK Inhibitors of Formula II,
Wherein Z is N



Compounds of formula II, wherein Z is N, may be
10 prepared as shown in the above synthetic scheme. The
synthetic scheme may be modified to provide other
compounds of formula II, wherein Z is N.

-123-

EXAMPLE 4

Cloning, Expression and Purification of JNK3 Protein

A BLAST search of the EST database using the published JNK3 α 1 cDNA as a query identified an EST clone (#632588) that contained the entire coding sequence for human JNK3 α 1. Polymerase chain reactions (PCR) using *pfu* polymerase (Stratagene) were used to introduce restriction sites into the cDNA for cloning into the pET-15B expression vector at the NcoI and BamHI sites. The protein was expressed in *E. coli*. Due to the poor solubility of the expressed full-length protein (Met 1-Gln 422), an N-terminally truncated protein starting at Ser residue at position 40 (Ser 40) was produced. This truncation corresponds to Ser 2 of JNK1 and JNK2 proteins, and is preceded by a methionine (initiation) and a glycine residue. The glycine residue was added in order to introduce an NcoI site for cloning into the expression vector. In addition, systematic C-terminal truncations were performed by PCR to identify a construct that give rise to diffraction-quality crystals. One such construct encodes amino acid residues Ser40-Glu402 of JNK3 α 1 and is preceded by Met and Gly residues.

The construct was prepared by PCR using deoxyoligonucleotides

25 5' GCTCTAGAGCTCCATGGGCAGCAAAAGCAAAGTTGACAA 3' (forward primer with initiation codon underlined) and
5' TAGCGGATCCTCATTCATTGAAATTCATTACTCCTTGTA 3' (reverse primer with stop codon underlined)
as primers and was confirmed by DNA sequencing. Control experiments indicated that the truncated JNK3 protein had an equivalent kinase activity towards myelin basic protein when activated with an upstream kinase MKK7 *in vitro*.

-124-

E. coli strain BL21 (DE3) (Novagen) was transformed with the JNK3 expression construct and grown at 30°C in LB supplemented with 100 µg/ml carbenicillin in shaker flasks until the cells were in log phase (OD₆₀₀ ~ 5 0.8). Isopropylthio-β-D-galactosidase (IPTG) was added to a final concentration of 0.8 mM and the cells were harvested 2 hours later by centrifugation.

E. coli cell paste containing JNK3 was resuspended in 10 volumes/g lysis buffer (50 mM HEPES, pH 10 7.2, containing 10% glycerol (v/v), 100 mM NaCl, 2 mM DTT, 0.1 mM PMSF, 2 µg/ml Pepstatin, 1µg/ml each of E-64 and Leupeptin). Cells were lysed on ice using a microfluidizer and centrifuged at 100,000 × g for 30 min at 4 °C. The 100,000 × g supernatant was diluted 1:5 with 15 Buffer A (20 mM HEPES, pH 7.0, 10% glycerol (v/v), 2 mM DTT) and purified by SP-Sepharose (Pharmacia) cation-exchange chromatography (column dimensions: 2.6 × 20 cm) at 4 °C. The resin was washed with 5 column volumes of Buffer A, followed by 5 column volumes of Buffer A 20 containing 50 mM NaCl. Bound JNK3 was eluted with a 7.5 column volume linear gradient of 50-300 mM NaCl. JNK3 eluted between 150-200 mM NaCl.

EXAMPLE 5

25 Activation of JNK3

5 mg of JNK3 was diluted to 0.5 mg/ml in 50 mM HEPES buffer, pH 7.5, containing 100 mM NaCl, 5 mM DTT, 20 mM MgCl₂ and 1 mM ATP. GST-MKK7(DD) was added at a molar ratio of 1:2.5 GST-MKK7:JNK3. After incubation for 30 30 minutes at 25°C, the reaction mixture was concentrated 5-fold by ultrafiltration in a Centriprep-30 (Amicon, Beverly, MA), diluted to 10 ml and an additional 1 mM ATP

-125-

added. This procedure was repeated three times to remove ADP and replenish ATP. The final addition of ATP was 5 mM and the mixture incubated overnight at 4°C.

The activated JNK3/GST-MKK7(DD) reaction mixture
5 was exchanged into 50 mM HEPES buffer, pH 7.5, containing
5 mM DTT and 5% glycerol (w/v) by dialysis or
ultrafiltration. The reaction mixture was adjusted to 1.1
M potassium phosphate, pH 7.5, and purified by hydrophobic
interaction chromatography (at 25 °C) using a Rainin
10 Hydropore column. GST-MKK7 and unactivated JNK3 do not
bind under these conditions such that when a 1.1 to 0.05 M
potassium phosphate gradient is developed over 60 minutes
at a flow rate of 1 ml/minute, doubly phosphorylated JNK3
is separated from singly phosphorylated JNK. Activated
15 JNK3 (i.e. doubly phosphorylated JNK3) was stored at -70°C
at 0.25-1 mg/ml.

EXAMPLE 6
JNK Inhibition Assays

20 Compounds were assayed for the inhibition of
JNK3 by a spectrophotometric coupled-enzyme assay. In
this assay, a fixed concentration of activated JNK3 (10
nM) was incubated with various concentrations of a
potential inhibitor dissolved in DMSO for 10 minutes at
25 30°C in a buffer containing 0.1 M HEPES buffer, pH 7.5,
containing 10 mM MgCl₂, 2.5 mM phosphoenolpyruvate, 200 µM
NADH, 150 µg/mL pyruvate kinase, 50 µg/mL lactate
dehydrogenase, and 200 µM EGF receptor peptide. The EGF
receptor peptide has the sequence KRELVEPLTPSGEAPNQALLR,
30 and is a phosphoryl acceptor in the JNK3-catalyzed kinase
reaction. The reaction was initiated by the addition of
10 µM ATP and the assay plate is inserted into the

-126-


spectrophotometer's assay plate compartment that was maintained at 30°C. The decrease of absorbance at 340 nm was monitored as a function of time. The rate data as a function of inhibitor concentration was fitted to 5 competitive inhibition kinetic model to determine the K_i .

-127-

CLAIMS

We claim:

1. A compound of the formula:



or a pharmaceutically acceptable derivative or prodrug

5 thereof; wherein

Y is selected from $-(CH_2)-Q_1$; $-(CO)-Q_1$; $-(CO)NH-Q_1$;
 Q_1 ; $-(CO)-O-Q_1$; $-(SO_2)-Q_1$ or $-(SO_2)NH-Q_1$;

10 Q_1 is a C₁-C₆ straight chain or branched alkyl or
 alkenyl group; a 5-7 membered aromatic or non-aromatic
 carbocyclic or heterocyclic ring; or a 9-14 membered
 bicyclic or tricyclic aromatic or non-aromatic carbocyclic
 or heterocyclic ring system, wherein said alkyl, alkenyl,
 ring or ring system is optionally substituted with one to
 four substituents, each of which is independently selected
 15 from NH₂, NH-R, N(R)₂, NO₂, OH, OR, CF₃, halo, CN, CO₂H,
 C(O)-NH₂, C(O)-NH-R, C(O)-N(R)₂, C(O)-R, SR, S(O)-R,
 S(O)₂-R, S(O)₂-NH-R or -R;

W is N or C;

wherein when W is N, R₈ is a lone pair of
 20 electrons; and

wherein when W is C, R₈ is R₇.A₁ is N or CR¹;A₂ is N or CR²;A₃ is N or CR³;25 A₄ is N or CR⁴;

-128-

provided that at least one of A₁, A₂, A₃ and A₄ must not be N;

R¹ is -NHR⁵, -OR⁵, -SR⁵, or -R⁵;

R², R³, and R⁴ are independently selected from -

5 (CO)NH₂, -(CO)NHR, -(CO)N(R)₂, -NHR⁵, -NHCH₂R⁵, -OR⁵, -SR⁵, -R⁵, -NH(CO)-R⁶, -NH(CO)-NHR⁶, -NH(CO)-NH(CO)R⁶, -NH(CO)-OR⁶, -NH(SO₂)-R⁶, -NH(SO₂)-NHR⁶, -C(O)OH, -C(O)OR, -(CO)-Q₁, -(CO)NH-Q₁, -(CO)NR-Q₁, -(CO)-O-Q₁, -(SO₂)-Q₁ or -(SO₂)NH-Q₁;

R⁵ and R⁶ are each independently selected from H;

10 N(R)₂, NHOH, NO₂, C(O)OR or halo; a C₁-C₆ straight chain or branched alkyl, alkenyl or alkynyl group; a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring; or a 9-14 membered bicyclic or tricyclic aromatic or non-aromatic carbocyclic or heterocyclic ring; wherein said 15 alkyl, alkenyl, ring or ring system is optionally substituted with one to four substituents, each of which is independently selected from NH₂, NHR, NHC(O)OR, N(R)₂, NO₂, OH, OR, CF₃, halo, CN, Si(R)₃, CO₂H, COOR, CONH₂, CONHR, CON(R)₂, COR, SR, S(O)R, S(O)₂R, S(O)₂NHR or R;

20 R⁷ is H; a C₁-C₆ straight chain or branched alkyl or alkenyl group; a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring; or a 9-14 membered bicyclic or tricyclic aromatic or non-aromatic carbocyclic or heterocyclic ring; wherein said alkyl, alkenyl, ring or 25 ring system is optionally substituted with one to four substituents, each of which is independently selected from NH₂, NHR, N(R)₂, NO₂, OH, OR, CF₃, halo, CN, CO₂H, CONH₂, CONHR, CON(R)₂, COR, SR, S(O)R, S(O)₂R, S(O)₂NHR or R;

30 R is a C₁-C₆ straight chain or branched alkyl or alkenyl group, a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring, or a 9-10 membered bicyclic aromatic or non-aromatic carbocyclic or

-129-

heterocyclic ring system; and

Z is CH or N.

2. The compound according to claim 1, wherein

5 Y is -(CH₂)₂-Q₁ and Q₁ is a substituted phenyl.

3. The compound according to claim 1, wherein
the compound is selected from any one of the compounds
depicted in Table 1.

10

4. A pharmaceutical composition comprising an
amount of a compound according to any one of claims 1 to 3
effective to inhibit JNK, and a pharmaceutically
acceptable carrier.

15

5. Use of the composition according to claim 4
for the manufacture of a medicament for treating or
preventing inflammatory diseases, autoimmune diseases,
destructive bone disorders, proliferative disorders,
20 infectious diseases, neurodegenerative diseases,
allergies, reperfusion/ischemia in stroke, heart attacks,
angiogenic disorders, organ hypoxia, vascular hyperplasia,
cardiac hypertrophy, thrombin-induced platelet aggregation
or conditions associated with proinflammatory cytokines in
25 a patient in need thereof.

6. The use according to claim 5, wherein said
treating or preventing is for an inflammatory disease
selected from acute pancreatitis, chronic pancreatitis,
30 asthma, allergies, or adult respiratory distress syndrome.

7. The use according to claim 5, wherein said

-130-

treating or preventing is for an autoimmune disease selected from glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis,
5 diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, or graft vs. host disease.

10

8. The use according to claim 5, wherein said wherein said treating or preventing is for a destructive bone disorders selected from osteoarthritis, osteoporosis or multiple myeloma-related bone disorder.

15

9. The use according to claim 5, wherein said wherein said treating or preventing is for a proliferative disease selected from acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's
20 sarcoma, or multiple myeloma.

10. The use according to claim 5, wherein said wherein said treating or preventing is for a neurodegenerative disease selected from Alzheimer's
25 disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral ischemia or neurodegenerative disease caused by traumatic injury, glutamate neurotoxicity or hypoxia.

30

11. The use according to claim 5, wherein said wherein said treating or preventing is for ischemia/reperfusion in stroke or myocardial ischemia,

-131-

renal ischemia, heart attacks, organ hypoxia or thrombin-induced platelet aggregation.

12. The use according to claim 5, wherein said
5 wherein said treating or preventing is for a condition
associated with T-cell activation or pathologic immune
responses.

13. The use according to claim 5, wherein said
10 wherein said treating or preventing is for an angiogenic
disorder selected from solid tumors, ocular
neovasculization, or infantile haemangiomas.

INTERNATIONAL SEARCH REPORT

In. national Application No

PCT/US 00/10866

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C07D209/40	A61K31/395	A61P43/00	C07D413/06	C07D405/06
	C07D417/06	C07D401/06	C07D403/06	C07D409/04	C07D409/14
	C07D405/14	C07D417/14	C07D401/14	C07F7/10	

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 16046 A (F. HOFFMANN-LA ROCHE AG) 30 May 1996 (1996-05-30) page 78, line 35 -page 79, line 2	1
X	EP 0 685 463 A (CHUGAI SEIYAKU KABUSHIKI KAISHA) 6 December 1995 (1995-12-06) page 30, line 26	1 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

18 September 2000

Date of mailing of the international search report

10/10/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 851 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Van Bijlen, H

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/10866

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CHEMICAL ABSTRACTS, vol. 99, no. 9, 29 August 1983 (1983-08-29) Columbus, Ohio, US; abstract no. 70513n, ZHAVRID, S. V. ET AL.: "Synthesis of indole derivatives and their antimicrobial activity." XP002147702 abstract & KHIM.-FARM. ZH., vol. 17, no. 2, - 1983 pages 153-158, -& DATABASE CHEMICAL ABSTRACTS 'Online' CA 99:70513, XP002147709 compound with RN 85731-64-2 and -63-1</p> <hr/> <p>CHEMICAL ABSTRACTS, vol. 90, no. 19, 7 May 1979 (1979-05-07) Columbus, Ohio, US; abstract no. 152060r, ABRAMENKO, P. I. ET AL.: "Synthesis of substituted indolothiazoles and thienothiazoles." XP002147703 abstract & ZH. VSES. KHIM. O-VA., vol. 23, no. 6, - 1978 pages 711-712, -& DATABASE CHEMICAL ABSTRACTS 'Online' CA 90:152060, XP002147710 compound with RN 69736-62-5 and -61-4</p> <hr/> <p>ARTHUR A. SANTILLI ET AL.: "7-Deazapurines VI. Syntheses and reactions of 5,7-dihydro-4-methyl-2-phenyl-7-substituted d-6H-pyrrolo(2,3-d)pyrimidin-6-ones" JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 13, - 1976 pages 135-137, XP002147701 HETERO CORPORATION. PROVO., US ISSN: 0022-152X * compound V *</p> <hr/> <p style="text-align: center;">-/-</p>	1
X		1
1		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/10866

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CHEMICAL ABSTRACTS, vol. 80, no. 6, 11 February 1974 (1974-02-11) Columbus, Ohio, US; abstract no. 31301e, PLANA, F. ET AL.: "N-Ethanol-beta-isatoxime." XP002147704 abstract & CRYST. STRUCT. COMMUN., vol. 2, no. 4, - 1973 pages 613-617, -& DATABASE CHEMICAL ABSTRACTS 'Online' CA 80:31301, XP002147711 compound with RN 51128-09-7</p> <hr/>	1
X	<p>CHEMICAL ABSTRACTS, vol. 82, no. 23, 9 June 1975 (1975-06-09) Columbus, Ohio, US; abstract no. 155017c, MIRAVITLLES C. ET AL.: "Determination of hydrogen bonds in organic compounds by x-ray diffraction." XP002147705 abstract & CIRC. FARM., vol. 32, no. 245, - 1974 pages 613-622, -& DATABASE CHEMICAL ABSTRACTS 'Online' CA 82:155017, XP002147712 compound with RN 41927-94-0</p> <hr/>	1
X	<p>CHEMICAL ABSTRACTS, vol. 76, no. 9, 28 February 1972 (1972-02-28) Columbus, Ohio, US; abstract no. 46035n, HIROSE, NORIYASU ET AL.: "Benzoheterocyclic derivatives. XI. Synthesis and pharmacological actions of indoline derivatives. 2." XP002147706 abstract & YAKUGAKU ZASSHI, vol. 91, no. 12, - 1971 pages 1323-1334, -& DATABASE CHEMICAL ABSTRACTS 'Online' CA 76:46035, XP002147713 compound with RN 34998-72-6 and 34943-89-0</p> <hr/> <p style="text-align: center;">-/-</p>	1

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/10866

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CHEMICAL ABSTRACTS, vol. 72, no. 24, 15 June 1970 (1970-06-15) Columbus, Ohio, US; abstract no. 128318p, IZQUIERDO, A. ET AL.: "Analytical applications of N-substituted beta-isatin oximes." XP002147707 abstract & INFORM. QUIM. ANAL., vol. 23, no. 6, - 1969 pages 161-168, -& DATABASE CHEMICAL ABSTRACTS 'Online! CA 72:128318, XP002147714 compound with RN 28318-57-2 and -56-1</p>	1
X	<p>CHEMICAL ABSTRACTS, vol. 73, no. 2, 13 July 1970 (1970-07-13) Columbus, Ohio, US; abstract no. 10333g, DIVIS, LUDVIK: "Analytically important reactions of isatin oximes." XP002147708 abstract & SB. VYS. SK. CHEM.-TECHNOL. PRAZE, ANAL. CHEM., vol. 3, - 1968 pages 85-112, -& DATABASE CHEMICAL ABSTRACTS 'Online! CA 73:10333, XP002147715 compound with RN 28150-91-6</p>	1
A	US 5 849 710 A (CARLO BATTISTINI ET AL.) 15 December 1998 (1998-12-15) column 1 -column 2	1,5
A	WO 99 01449 A (NOVARTIS AG) 14 January 1999 (1999-01-14) page 20; claim 2	1,5
A	WO 94 18194 A (PFIZER INC.) 18 August 1994 (1994-08-18) page 6, line 28 - line 30 page 13, line 26 - line 31; claim 1	1,5
P,X	WO 99 51590 A (BOEHRINGER INGELHEIM PHARMA KG) 14 October 1999 (1999-10-14) * example 10(a), 10.1(a), 11(a), 11.1(a) and 11.2(a) *	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Application No

PCT/US 00/10866

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9616046	A 30-05-1996	AU 704911 B AU 4116196 A BR 9509768 A CN 1166831 A CZ 9701575 A EP 0793656 A FI 972194 A HU 77372 A JP 11507009 T NO 972393 A PL 320458 A TR 960499 A US 5763450 A		06-05-1999 17-06-1996 07-07-1998 03-12-1997 17-09-1997 10-09-1997 22-05-1997 30-03-1998 22-06-1999 29-05-1997 29-09-1997 21-07-1996 09-06-1998
EP 685463	A 06-12-1995	AU 6044894 A FI 953866 A NO 953235 A PL 310168 A RU 2128170 C CA 2156287 A CN 1117727 A, B CZ 9502096 A HU 74105 A JP 7048349 A WO 9419322 A SG 67938 A US 6031111 A US 5952511 A ZA 9401092 A		14-09-1994 16-08-1995 09-10-1995 27-11-1995 27-03-1999 01-09-1994 28-02-1996 13-12-1995 28-11-1996 21-02-1995 01-09-1994 19-10-1999 29-02-2000 14-09-1999 08-03-1995
US 5849710	A 15-12-1998	EP 0764152 A JP 10501821 T WO 9632380 A		26-03-1997 17-02-1998 17-10-1996
WO 9901449	A 14-01-1999	AU 8801598 A EP 0993456 A NO 996429 A ZA 9805656 A		25-01-1999 19-04-2000 23-12-1999 30-12-1998
WO 9418194	A 18-08-1994	AT 145206 T CA 2155664 A DE 69305999 D DE 69305999 T DK 683777 T EP 0683777 A ES 2097025 T FI 940568 A GR 3021924 T JP 2709530 B JP 8502517 T US 5607959 A		15-11-1996 18-08-1994 19-12-1996 06-03-1997 28-04-1997 29-11-1995 16-03-1997 10-08-1994 31-03-1997 04-02-1998 19-03-1996 04-03-1997
WO 9951590	A 14-10-1999	DE 19815020 A AU 3703499 A US 6043254 A		07-10-1999 25-10-1999 28-03-2000